Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Justin Pandoo

Internal Medicine Conway, SC Medical Doctor

NPI 1659755361 CMS profile 5690062

2367B Cypress Cir, Conway, SC 29526

Open in the dashboard

General payments

$5,200

332 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Justin Pandoo of Conway, SC is reported in the CMS Open Payments database as having received $5,200 across 332 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $447 38
2022 General $1,458 76
2021 General $1,285 76
2020 General $1,364 93
2019 General $645 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Justin Pandoo
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Justin Pandoo were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Justin Pandoo Internal Medicine median Middle half National median
2019 $645 $159 $48–$570 $163
2020 $1,364 $119 $33–$402 $114
2021 $1,285 $135 $37–$521 $132
2022 $1,458 $141 $42–$496 $149
2023 $447 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Lilly USA, LLC $614 44 payments
  2. Novo Nordisk Inc $469 22 payments
  3. AbbVie, Inc. $453 50 payments
  4. AstraZeneca Pharmaceuticals LP $449 24 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $321 17 payments
  6. GlaxoSmithKline, LLC. $307 11 payments
  7. Amarin Pharma Inc. $287 16 payments
  8. Allergan Inc. $277 30 payments
  9. Sanofi-Aventis U.S. LLC $273 16 payments
  10. Pfizer Inc. $198 11 payments
  11. Other $1,552 91 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $5,200 332 payments
Products named General payments · program years 2019–2023
  1. RYBELSUS $429 19 payments
  2. Kerendia $321 17 payments
  3. Vascepa $287 16 payments
  4. TRELEGY ELLIPTA $272 8 payments
  5. Ozempic $243 15 payments
  6. FARXIGA $234 13 payments
  7. CONTRAVE $193 16 payments
  8. JARDIANCE $187 16 payments
  9. MOUNJARO $185 10 payments
  10. TRINTELLIX $177 10 payments
  11. Other $3,560 258 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 117 drugs

Part D claims

6,880

Median for Internal Medicine: 777

Drug cost

$426,254

Median for Internal Medicine: $73,373

Branded share of claims

14.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 85 $102,748
Eliquis Apixaban Brand 66 $78,650
Farxiga Dapagliflozin Propanediol Brand 23 $30,791
Jardiance Empagliflozin Brand 21 $27,928
Mounjaro Tirzepatide Brand 18 $20,848
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 22 $19,157
Xarelto Rivaroxaban Brand 17 $17,336
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 15 $17,138
Linzess Linaclotide Brand 20 $12,841
Januvia Sitagliptin Phosphate Brand 11 $11,371

The 10 drugs with the highest cost, of 117 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 118 billing codes

Paid by Medicare

$189,538

Of which drugs: $15,475

Medicare patients

438

Average age 77

Services billed

6,823

203 women, 235 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Ischemic heart disease 35%
Diabetes 31%
Chronic kidney disease 30%
Atrial fibrillation 22%
Cancer 20%
Osteoporosis 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 64 64 $5,236

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

332 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record